• Our Company
    • Key Facts
    • Leadership
    • Governance
    • History
    • Compliance & Ethics
    • Diversity & Inclusion
    • Our Websites
    • Achievements
    • Business Information
  • R&D
    • R&D Strategy
    • In the Pipeline
    • Disease Areas of Focus
    • Our R&D
    • Our Science
    • R&D Highlights
    • Major R&D Facilities
    • Clinical Trials
  • Products
    • Patient Assistance Programs
    • Prescribing Information
    • R&D
    • Clinical Trials
    • Counterfeit Drugs
  • News
    • Press Releases
    • Publications
    • Media Library
    • Key Facts
    • Leadership
    • Financial Reporting
    • Features
    • Achievements
    • Media Contacts
    • Subscribe to e-mail alerts
  • Investors
    • Key Facts
    • Stock Information
    • SEC Filings
    • Financial Reporting
    • Events & Presentations
    • Shareholder Services
    • Investor Contacts
  • Partnering
    • Why Partner With Us?
    • Areas of Interest
    • Our Process
    • Our Partners
    • Partnering News
    • Partnering Contact
  • Responsibility
    • Bristol-Myers Squibb Foundation
    • Sustainability
    • Patient Assistance Programs
    • Building Our Communities
    • Grants & Giving
    • Position on Key Issues
    • Clinical Trials
    • Combating Counterfeit Drugs
    • Achievements
  • Careers
    • Job Opportunities
    • Our Culture
    • Diversity & Inclusion
    • Developing Our People
    • University Recruitment
    • Achievements
    • Benefits
    • Manage My Profile
    • Apply Now
Go Search

SITE INDEX|CONTACT US|TERMS|PRIVACY
Health Care Professionals Access medical information and resources
Clinical Trials Bristol-Myers Squibb-sponsored clinical trials
Need Help Paying for Your Bristol-Myers Squibb Medicines? Learn about our assistance programs.
August 20, 2009
Derivative Action Settlement Notice
Our Environmental Stewardship
 
Newsweek
Bristol-Myers Squibb
Among Greenest
Companies
Ranked 8th among 500 by Newsweek. With nearly all Sustainability 2010 Goals met, we're refocusing on
new horizons.

LATEST NEWS
November 5, 2009FDA Approves Labeling Update for REYATAZ® (atazanavir sulfate) Capsules to Include 96-Week Data for Previously Untreated HIV-1 Infected Adult PatientsOctober 31, 2009BARACLUDE® (entecavir) Demonstrated Greater Antiviral Efficacy Compared to Adefovir in New Study of Chronic Hepatitis B Patients with Evidence of Decompensated CirrhosisOctober 31, 2009Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis COctober 29, 2009Bristol-Myers Squibb Donation to Benefit Students at The Pennington School and Beyond
 

News RSS
 
 
 

© 2009 Bristol-Myers Squibb
Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.